Literature DB >> 30654090

Dosimetric Correlates of Pulmonary Toxicity in Patients with Malignant Pleural Mesothelioma Receiving Radiation Therapy to the Intact Lungs.

Marcher R Thompson1, Vishruta A Dumane1, Stanislav A Lazarev1, Yaseen Zia2, Kenneth E Rosenzweig3.   

Abstract

PURPOSE: We aimed to determine dose-volume constraints that correlate with severe (grade ≥3) radiation pneumonitis (RP) in patients diagnosed with malignant pleural mesothelioma, treated using volumetric modulated arc therapy. METHODS AND MATERIALS: Data from 40 patients with malignant pleural mesothelioma who underwent pleurectomy decortication and adjuvant radiation therapy at our institution between December 2010 and October 2016 were retrospectively analyzed. Dosimetric variables for the absolute volume and percentage volume of the ipsilateral lung, contralateral lung, and heart were recorded. Events of RP were assessed using the Common Terminology Criteria for Toxicity and Adverse Events, version 4.0. The statistical analysis with Wilcoxon rank-sum, Spearman rank correlation, and receiver operating characteristic curves was computed using MATLAB V9.1, RV3.4, and SAS V9.4.
RESULTS: Of the 40 patients, 26 patients (65%) were male. The median age at the time of diagnosis was 66.5 years (range, 44-84 years). The median prescription dose was 45 Gy (range, 30-54 Gy). Five patients (12.5%) had grade ≥3 RP. The incidence of grade≥ 3 RP showed a significant correlation (P < .05) with the absolute volume and percentage volume of the ipsilateral lung spared of ≥20 Gy (55 cc; 7%) and spared of ≥30 Gy (200 cc; 23%). Dosimetric variables of the contralateral lung, total lung, and heart did not show a correlation with incidence of grade ≥3 RP.
CONCLUSIONS: In our cohort, sparing the ipsilateral lung of at least 55 cc of 20 Gy and 200 cc of 30 Gy correlated with a reduced incidence of severe (grade ≥3) RP.
Copyright © 2019 American Society for Radiation Oncology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2019        PMID: 30654090      PMCID: PMC6500743          DOI: 10.1016/j.prro.2018.12.008

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  15 in total

1.  Basic principles of ROC analysis.

Authors:  C E Metz
Journal:  Semin Nucl Med       Date:  1978-10       Impact factor: 4.446

Review 2.  Radiation dose-volume effects in the lung.

Authors:  Lawrence B Marks; Soren M Bentzen; Joseph O Deasy; Feng-Ming Spring Kong; Jeffrey D Bradley; Ivan S Vogelius; Issam El Naqa; Jessica L Hubbs; Joos V Lebesque; Robert D Timmerman; Mary K Martel; Andrew Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

3.  Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery.

Authors:  Marjorie G Zauderer; Lee M Krug
Journal:  Ann Cardiothorac Surg       Date:  2012-11

4.  Novel radiation therapy approaches in malignant pleural mesothelioma.

Authors:  Andreas Rimner; Kenneth E Rosenzweig
Journal:  Ann Cardiothorac Surg       Date:  2012-11

5.  Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.

Authors:  Kenneth E Rosenzweig; Marjorie G Zauderer; Benjamin Laser; Lee M Krug; Ellen Yorke; Camelia S Sima; Andreas Rimner; Raja Flores; Valerie Rusch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-05-18       Impact factor: 7.038

6.  Tomotherapy after pleurectomy/decortication or biopsy for malignant pleural mesothelioma allows the delivery of high dose of radiation in patients with intact lung.

Authors:  Emilio Minatel; Marco Trovo; Jerry Polesel; Imad Abu Rumeileh; Tania Baresic; Alessandra Bearz; Alessandro Del Conte; Giovanni Franchin; Carlo Gobitti; Annalisa Drigo; Andrea Dassie; Vittore Pagan; Mauro G Trovo
Journal:  J Thorac Oncol       Date:  2012-12       Impact factor: 15.609

7.  Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma.

Authors:  David C Rice; W Roy Smythe; Zhongxing Liao; Thomas Guerrero; Joe Y Chang; Mary F McAleer; Melenda D Jeter; Arlene Correa; Ara A Vaporciyan; H Helen Liu; Ritsuko Komaki; Kenneth M Forster; Craig W Stevens
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-04-30       Impact factor: 7.038

8.  Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma.

Authors:  Lee M Krug; Harvey I Pass; Valerie W Rusch; Hedy L Kindler; David J Sugarbaker; Kenneth E Rosenzweig; Raja Flores; Joseph S Friedberg; Katherine Pisters; Matthew Monberg; Coleman K Obasaju; Nicholas J Vogelzang
Journal:  J Clin Oncol       Date:  2009-04-13       Impact factor: 44.544

9.  Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

Authors:  Raja M Flores; Harvey I Pass; Venkatraman E Seshan; Joseph Dycoco; Maureen Zakowski; Michele Carbone; Manjit S Bains; Valerie W Rusch
Journal:  J Thorac Cardiovasc Surg       Date:  2008-02-14       Impact factor: 5.209

10.  Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.

Authors:  Andreas Rimner; Daniel E Spratt; Marjorie G Zauderer; Kenneth E Rosenzweig; Abraham J Wu; Amanda Foster; Ellen D Yorke; Prasad Adusumilli; Valerie W Rusch; Lee M Krug
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-07-26       Impact factor: 7.038

View more
  1 in total

1.  Biological Pathways Associated With the Development of Pulmonary Toxicities in Mesothelioma Patients Treated With Radical Hemithoracic Radiation Therapy: A Preliminary Study.

Authors:  Sergio Crovella; Alberto Revelant; Elena Muraro; Ronald Rodrigues Moura; Lucas Brandão; Marco Trovò; Agostino Steffan; Paola Zacchi; Giuliano Zabucchi; Emilio Minatel; Violetta Borelli
Journal:  Front Oncol       Date:  2021-12-22       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.